Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.23.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Jun. 30, 2023
Current assets:    
Cash and cash equivalents $ 148,663 $ 180,571
Short-term available-for-sale investments   23,739
Accounts receivable, less allowance for doubtful accounts of $4,920 and $4,738, respectively 204,570 218,468
Inventories 186,080 171,638
Other current assets 52,164 27,066
Total current assets 591,477 621,482
Property and equipment, net 231,683 226,200
Right of use asset 102,277 98,326
Goodwill 969,376 872,737
Intangible assets, net 578,971 534,645
Other assets 281,576 285,302
Total assets 2,755,360 2,638,692
Current liabilities:    
Trade accounts payable 28,084 25,679
Salaries, wages and related accruals 34,891 36,747
Accrued expenses 15,937 14,880
Contract liabilities 24,516 23,069
Income taxes payable 5,938 12,022
Operating lease liabilities - current 12,198 11,199
Contingent consideration payable 1,750 3,500
Other current liabilities 4,440 1,413
Total current liabilities 127,754 128,509
Deferred income taxes 83,134 88,982
Long-term debt obligations 440,000 350,000
Operating lease liabilities 97,332 93,766
Other long-term liabilities 9,394 10,919
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 158,354,579 and 157,641,914 respectively 1,584 1,576
Additional paid-in capital 746,606 721,543
Retained earnings 1,327,572 1,309,461
Accumulated other comprehensive loss (78,016) (66,064)
Total Bio-Techne's shareholders' equity 1,997,746 1,966,516
Total shareholders' equity 1,997,746 1,966,516
Total liabilities and shareholders' equity $ 2,755,360 $ 2,638,692